Insider Stock Trading History of Omenn Gilbert S


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Omenn Gilbert S since year 2005. The trader's CIK number is 1184227. At the time of this reporting, Omenn Gilbert S is the Director of Esperion Therapeutics, Inc. . (stock ticker symbol ESPR). See this page for all insider trading activities at Esperion Therapeutics, Inc. .

Note that in the past OMENN GILBERT S also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Omenn Gilbert S since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-03-21 ESPR Esperion Therapeutics, Inc. Buy 1,000 42.26 42,260
2016-03-01 ESPR Esperion Therapeutics, Inc. Buy 5,000 15.28 76,400
2014-10-21 ESPR Esperion Therapeutics, Inc. Buy 5,000 20.00 100,000
2012-11-26 AMGN Amgen Inc Option Ex 26,000 62.74 1,631,240
2012-11-26 AMGN Amgen Inc Sale 26,000 87.11 2,264,990
2012-02-29 AMGN Amgen Inc Option Ex 5,000 58.61 293,050
2011-12-22 AMGN Amgen Inc Option Ex 16,000 56.30 900,800
2008-12-08 AMGN Amgen Inc Sale 16,000 58.14 930,240
2008-12-08 AMGN Amgen Inc Option Ex 16,000 28.97 463,488
2008-01-25 AMGN Amgen Inc Option Ex 1,000 45.45 45,450
2008-01-25 AMGN Amgen Inc Option Ex 1,000 45.45 45,450
2008-01-23 AMGN Amgen Inc Option Ex 16,000 12.28 196,496
2006-03-03 AMGN Amgen Inc Sale 1,600 76.80 122,872
2006-03-01 AMGN Amgen Inc Sale 2,000 60.95 121,892
2006-02-22 AMGN Amgen Inc Sale 6,000 75.09 450,558
2006-01-25 AMGN Amgen Inc Option Ex 9,600 14.72 141,302
2005-10-05 RHEO Occulogix, Inc. Buy 2,500 6.42 16,062

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Omenn Gilbert S (Director of Esperion Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.